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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Blockade of advanced glycation end-products (AGE) is able to reduce
diabetic complications and control periodontitis. This study aimed to determine whether
the application of aminoguanidine (AG), an AGE inhibitor, or N-phenacylthiazolium bromide
(PTB), an AGE breaker, facilitates the healing of an osseous wound in non-diabetic animals.
Methods: 2.6 mm diameter full-thickness osseous wounds were created bilaterally in 54
healthy SpragueeDawley rats. Rats received daily normal saline, AG, or PTB injections respec-
tively and were euthanized after 7 days, 14 days, or 28 days (n Z 6). The wound healing
pattern was assessed by micro-computed tomography, histology, histochemistry for the fiber
arrangement, and the gene expression levels of AGE receptor, tumor necrosis factor-a, type
I collagen, and fibronectin.
Results: Under the AG and PTB administration, osteogenesis was apparently promoted in the
early stages of healing, but the union of the osseous wound and the fibril re-arrangementeclare no conflicts of interest related to the study.
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974 S.-C. Tsai et al.Figure 1 (A) The study design. A
tration of the osseous wound in the
the dashline indicates the path o
NS Z normal saline; PTB Z N-phenwas apparently retarded. No significant difference was found in any of the micro-computed to-
mography parameters as compared to the control in the first 14 days, whereas the relative
bone volume was significantly higher in the control at Day 28. AGE receptor and tumor necrosis
factor-a were depressed in the PTB group, but only temporarily at Day 14 in the AG group.
Therefore, at Day 14, type I collagen was significantly upregulated in the PTB group, and fibro-
nectin was significantly increased in the AG group.
Conclusion: Anti-AGE agents reduced inflammation but did not apparently facilitate osteogen-
esis during the osseous wound repair.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
The healing of the osseous wound generated by periodontal
inflammation, osseous surgery, or the enucleation of cysts
or tumors involves complex molecular signaling.1e3 The
harmonization of destructive and reconstructive phases is
one of the prerequisites for achieving bone regeneration.4,5
Inflammation, an immediate immunological response after
injury, is a determining factor for tissue destruction.6
However, the inhibition of inflammation was also reported
to damage the bone tissue.6 Modulation of inflammation to
facilitate the healing process has not been confirmed.
Advanced glycation end-products (AGE), the irreversible
adducts from the nonenzymatic glycosylation of proteins or
lipids,7,8 have been found to accumulate in patients with
severe metabolic or immunological disturbances or with
extensive inflammation or degeneration.9e11 AGE have
been reported to interfere with cell-matrix interactions by
the alteration of cross-linking of the extracellular matrix.12
The engagement of the cellular receptor for AGE (RAGE)
may induce an increase in oxygen tension and lead to the
production of inflammatory cytokines.13,14 Our recenttotal of 54 animals (6/group/t
mandible. The standardized def
f the mandibular canal. AG Z
acylthiazolium bromide.investigations demonstrated that AGEeRAGE axis activation
occurs in parallel with experimental periodontitis progres-
sion and was evident in the early stage of dento-alveolar
osseous wound healing of nondiabetic animals.15,16 Anti-
AGE agents, including aminoguanidine (AG), an AGE inhib-
itor, and N-phenacylthiazolium bromide (PTB), an AGE
breaker, have been reported to inhibit the induction of
experimental periodontitis of nondiabetic animals as well
as to promote cellular viability in the nondiabetic and
noninflammatory condition in vitro.17,18 The potential
modulatory mechanisms are the reduction of inflammation
and the increase of matrix synthesis.19,20 However, in-
flammatory destruction recovery is only facilitated with
PTB administration. This outcome is presumably related to
the limited effect of AG on the highly concentrated pre-
existing AGE in the sites of periodontitis.17,18
In this study, we examined the therapeutic potential of
anti-AGE agents in the facilitation of osseous wound repair
in rats. The efficacy of AG and PTB was investigated
respectively by micro-computed tomography (micro-CT),
histology, and expression profiles of RAGE, tumor necrosis
factor-a (TNF-a), type I collagen, and fibronectin.ime point) and 108 sites (2/animal) were evaluated. (B) Illus-
ect was created using a 2.6 mm diameter customized drill, and
aminoguanidine; micro-CT Z micro-computed tomography;
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Animal models
All of the animal procedures performed followed the
approved protocol number 20130054 from the Institutional
Animal Care and Use Committee of the National Taiwan
University, Taipei, Taiwan. Fifty-four male SpragueeDaw-
ley rats (250e300 g) were utilized. The study design is
illustrated in Fig. 1A, and the sample size was determined
by power analysis based on the results from our previous
study.15 We assumed at least 15% difference in relative
bone volume between the control and treatment groups,
80% power, a Z 0.05, and normal distribution and equiva-
lent variance of the samples. Thus, at least six animals/
treatment group/time point were used in this study. A
2.6 mm diameter full-thickness osseous defect was created
using a customized dental drill on both sides of the
mandible of each rat (Fig. 1B). Animals received daily in-
jections of normal saline (control), 100 mg/kg AG (Sigma-
Aldrich, St Louis, MO, USA), or 5 mg/kg PTB (Ariel Chemical
Co. Ltd., Wuhan, China) and were euthanized at 7 days, 14
days, or 28 days after the creation of the defects (n Z 6/
treatment/time point). From the harvested mandible, tis-
sues within the osseous wound in one randomly selected
side were excised for the evaluation of gene expression
levels, and the other side of the mandible was fixed in 10%Figure 2 Osseous wound repair pattern from a slice of micro-
bounded by the dashline indicates the wound edges of the contro
nacylthiazolium bromide.formaldehyde for microcomputed tomography micro-CT
imaging and histological examinations.
Micro-CT
The harvested mandibles were examined by Siemens Inveon
CT System (Siemens Healthcare, Erlangen, Germany) with
an 80-W tungsten anode, a 30e80-kVp variable focus X-ray
source, and a 165-mm detector to achieve an effective
pixel size of 19 mm  19 mm  19 mm (or 0.019 mm  0.019
mm  0.019 mm). The entire osteotomy site was selected
as the region of interest, and the micromorphometric bone
parameters, including relative bone volume (BV/TV),
trabecular thickness (Tb.Th), trabecular separation
(Tb.Sp), and trabecular number (Tb.N), were separately
calculated for each region of interest using CTAn software
(Skyscan, Kontich, Belgium).
Histology
After fixation, the mandibles were decalcified with 12.5%
ethylenediaminetetraacetic acid and embedded in paraffin.
Two 5 mm sections from the horizontal plane of the center
of the osseouswoundwere selected.One sectionwas stained
with hematoxylin and eosin for histological assessment, and
the other with Masson’s Trichrome to evaluate the collagen
configurations. All of the images were acquired utilizingcomputed tomography imaging from day 7 to 28. The region
l specimens at Day 28. AG Z aminoguanidine; PTB Z N-phe-
Figure 3 Quantitative micro-computed tomography assessments. (A) Relative bone volume (BV/TV). (B) Trabecular thickness
(Tb.Th). (C) Trabecular number (Tb.N). (D) Trabecular separation (Tb.Sp). Aminoguanidine (AG) or N-phenacylthiazolium bromide
(PTB) group compared to control group at the same time point: *p < 0.05.
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Germany), and closure of the osseous defect was evaluated
by themeasurement of the distance between the two ends of
the osseous edges as measured under 40 magnification.
Real-time polymerase chain reaction analysis
The RNA harvested from the tissue was transferred to cDNA
utilizing iScript cDNA Synthesis Kit (Bio-Rad Laboratories,
Hercules, CA, USA), and the mRNA levels of genes were
quantitatively analyzed by StepOnePlus real-time polymer-
ase chain reaction system (Applied Biosystems and Life
Technologies, Grand Island, NY, USA) and sequence-specific
TaqMan gene expression assays (Applied Biosystems and Life
Technologies, Grand Island, NY, USA) for GAPDH (house-
keeping gene), RAGE, TNF-a, type I collagen (major extra-
cellular matrix protein in the periodontium), and fibronectin
(extracellular matrix protein for cell attachment). Because
the mRNA levels of bone-specific genes, including osteo-
pontin and osteocalcin, were not detectable in most har-
vested specimens of our preliminary trials, the assessment of
bone-specific genes was excluded in the present study. The
gene expression levels were normalized to GAPDH, and data
were evaluated compared to the relative expression of the
averaged levels of the control group at the same time point.
All experiments were performed in triplicate.
Statistical analysis
One-way ANOVA followed by Tukey’s post hoc test were
used to compare the differences between the control andAG or PTB-treated groups at each time point. The data are
presented as the mean  standard deviation of measure-
ments, with p < 0.05 considered to be statistically
significant.
Results
Gross observations
All animals recovered uneventfully from the anesthesia and
interventions and survived until the date of euthanasia.
However, swelling in the submandibular area was noted in
all animals during the first 3 days, which was completely
resolved at Day 7, without observable differences among
groups (data not shown).
Osseous wound repair from the micro-CT imaging
Mineralization initiated at the wound edges in all groups at
Day 7 (Fig. 2, upper panel). At Day 14, the wound was
apparently completely filled with bone spongiosa in the
control group, whereas partially wound fill and the union of
the newly-formed bone from the wound edges was noted in
the AG and PTB groups (Fig. 2, middle panel). At Day 28, the
border of the osseous wound was generally indistinguish-
able in the control group (Fig. 2, lower panel). Greater
wound fill was noted in the AG and PTB groups relative to
Day 14, with thicker bone spongiosa noted in the PTB group.
However, mineralization of the AG and PTB groups was
obviously inferior relative to the control group.
Figure 4 Histological assessments of the osseous wound. (A) A site of a normal saline (NS)-treated animal at Day 7. (B) A site of an
N-phenacylthiazolium bromide-treated animal at Day 7. (C) A site of an NS-treated animal at Day 14. (D) A site of an
aminoguanidine-treated animal at Day 14. (E) A site of an NS-treated animal at Day 28. (F) A site of an NS-treated animal at Day 28.
Arrows indicate the wound edge, and asterisks indicate the newly-formed bone. Magnification: 100; scale bar: 100 mm.
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Generally, all of the micro-CT parameters, except Tb.Sp,
gradually increased and appeared to reach a steady status
at Day 14 in the AG and PTB groups, whereas the persistent
increase of mineralization was noted in the control group
until Day 28 (Fig. 3AeC). BV/TV was slightly higher in the
AG and PTB groups relative to the control at Day 7, and no
obvious difference was noted among all three groups at Day
14 (Fig. 3A). However, BV/TV was significantly higher in the
control relative to the AG and PTB groups at Day 28. No
obvious difference in Tb.Th and Tb.N was noted among all
three groups at Day 7 and Day 14 (Fig 3B and C), and the
control group demonstrated significantly greater Tb.Th
than that of the AG and PTB groups at Day 28 (p < 0.05,
Fig. 3B). Tb.Sp was slightly and insignificantly greater in the
PTB group relative to the AG and control groups at Day 14,
whereas no obvious difference in Tb.Sp was noted among
the three groups at Day 7 and Day 28 (Fig. 3D).
Descriptive histology
At Day 7, the osseous wound was mainly occupied with
fibrous tissue. The osteogenesis was immature andrestricted at the edge of the wound in the control group
(Fig. 4A). In the AG and PTB groups, the newly-formed bone
appeared to be evenly distributed within the wound
(Fig. 4B). At Day 14, the union of the osseous wound by the
thin lamellar bone was noted. The edge of the osseous
wound was still distinguishable in the control group
(Fig. 4C). The newly-formed bone was apparently thicker
and evidently deposited in the inner native bone surface of
the AG and PTB groups, whereas the union of the osseous
wound was not observed (Fig. 4D). Therefore, at Day 28,
the osseous wounds were invisible in four specimens of the
control group, two specimens of the AG group, and two
specimens of the PTB group (data not shown). Histologi-
cally, the newly-formed bone was corticalized and without
distinguishable junction to the native bone in the control
group (Fig. 4E). Although the bone trabeculae were thicker
and better organized relative to those at Day 14, cortical-
ization was still not achieved in most specimens of the AG
and PTB groups at Day 28 (Fig. 4F).
Observations under Masson’s trichrome staining
At Day 7, the wound edge was occupied with loose fibrous
matrix and thin spongiosa in the control group (Fig. 5A). In
Figure 5 Observations under Masson’s Trichrome staining. (A) A site of a normal saline (NS)-treated animal at Day 7. (B) A site of
an N-phenacylthiazolium bromide-treated animal at Day 7. (C) A site of an NS-treated animal at Day 14. (D) A site of an
aminoguanidine-treated animal at Day 14. (E) A site of an NS-treated animal at Day 28. (F) A site of an NS-treated animal at Day 28.
Arrows indicate the wound edge, and asterisks indicate the newly-formed bone. Magnification: 400; scale bar: 50 mm.
978 S.-C. Tsai et al.the AG and PTB groups, a fibril matrix was apparently
densely aligned in the neogenic bone, and the bone surface
was relatively flat compared to the control group. Higher
cellularity with fewer interposed collagen fibrils was noted
in the remainder of the wound area (Fig. 5B). The bone
trabeculae appeared to be thicker at Day 14 and Day 28 in
all three groups (Fig. 5CeF). However, in the AG and PTB
groups, the fibril arrangement was apparently different in
the native and newly-formed bone at Day 14 (Fig. 5D), and
the border between the native and newly-formed bone was
clearly distinguishable at Day 28 (Fig. 5F).
Gene expression profiles
RAGE was apparently downregulated in PTB-treated ani-
mals from Day 7 to Day 28 and significantly downregulated
in both AG and PTB groups (p < 0.05) at Day 14 (Fig. 6A).TNF-a was significantly downregulated in the PTB group at
Day 7 (p < 0.05) and Day 14 (p < 0.01) and in the AG group
at Day 14 (p < 0.05, Fig. 6B). The type I collagen level was
significantly higher in the PTB group relative to the control
group at Day 14 (p < 0.05), whereas a difference was not
obvious at Day 28 (Fig. 6C). Fibronectin was apparently
higher in the AG group relative to that of all other groups
(Fig. 6D), and a significant difference compared to the
control was noted at Day 14 (p < 0.05).
Discussion
The accumulation of AGE and the activation of the
AGEeRAGE axis have been shown to affect wound healing
dynamics in diabetics. Blockade of this signaling pathway
facilitated the recovery phase.21 The existence of the
AGEeRAGE axis could also directly influence the activities
Figure 6 Gene expression in the osseous wound. (A) Receptor for advanced glycation end-products (RAGE). (B) Tumor necrosis
factor-a (TNF-a). (C) Type I collagen. (D) Fibronectin. Aminoguanidine (AG) or N-phenacylthiazolium bromide (PTB) group
compared to control group at the same time point: *p < 0.05, **p < 0.01.
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impaired formation of the osseous tissue in the diabetes.22
Given that the activation of the AGEeRAGE axis is promi-
nent in the early reparative stage of the periodontal
osseous defect in systemically healthy rats and that the
level was parallel to the degree of inflammation,15 the
present study might be the first report of the antiglycation
treatment in osseous wound repair. The results demon-
strate that neo-osteogenesis was apparently accelerated
with the treatment of anti-AGE agents (i.e., AG or PTB) at
Day 7 (Figs. 4B and 5B). This effect might be related to the
inhibition of inflammation via the downregulation of the
AGEeRAGE signaling pathway (Fig. 6A and B). However, no
significant difference was noted in any of the micro-CT
parameters at this stage (Fig. 3). As Kim et al23 demon-
strated, the differentiation process of the neuron precursor
cells was unlikely triggered but potentially promoted by
RAGE signaling. It is inferred that the differentiation po-
tential of osteoprogenitor cells was also not directly trig-
gered in the present study, and thus the promotion of
osteogenesis was limited.
Following the recession of inflammation, the levels of
RAGE and TNF-a in the AG and PTB groups were not
significantly different from those of the control group at
Day 28 (Fig. 6A and B). However, osteogenesis as well as the
union of the osseous wound was apparently retarded in the
AG and PTB groups (Figs. 3 and 4). Unlike the control,
newly-formed bone was deposited in the inner surface of
the mandible with a distinctly different fibril arrangement
than the native bone (Fig. 5D and F), presumably due to theresultant hypoglycosylation caused by the persistent anti-
glycation treatment. Hypoglycosylation had been reported
to affect the structural integrity and force transmission
between the cytoskeleton and the extracellular matrix
and to lead to peripheral tissue dystrophy in extreme
cases,24,25 and a similar situation might apply to the healing
osseous wound. Thus, the upregulation of structural matrix
expression in the AG and PTB groups at Day 14 (Fig. 6C and
D) might not necessarily lead to the facilitation of the
osseous wound repair in the later stage. By contrast, in
order to confirm the capability of osteogenesis, examina-
tions on the expression levels of bone-specific markers
would be needed.
The inhibition of RAGE-regulated signaling was appar-
ently different in the AG and PTB groups. RAGE and TNF-a
were downregulated at Day 7 and sustained until Day 28 in
the PTB group, whereas the downregulation of RAGE and
TNF-a was only prominent at Day 14 in the AG group (Fig. 6A
and B). This difference may be due to the short plasma half-
life (<1 hour) of AG, whereby the high AG concentration
required to trap dicarbonyl intermediates to inhibit AGE
formation and reduce inflammation as well.26 Therefore, as
inflammation in the current model was relatively low and
was only elicited immediately after the creation of the
defect, the resultant promotive effect in the osseous
wound repair was consequently similar in both the AG and
PTB groups.
The study has limitations. Firstly, the pattern and etiol-
ogy of the osseous defect are different from those in human
jaw bones, and the size of the defect was relatively small
980 S.-C. Tsai et al.due to the limited size of rat jaw bone and the proximity of
the mandibular canal to the mandibular border. The pattern
and dynamics of wound healing observed in this study might
differ from the clinical conditions in humans. Secondly, AG
and PTB were systemically administrated without targeting
to the specific tissue, and the dose utilized was a single
effective dose in the modulation of experimental peri-
odontitis.17,18 The concentration might be suboptimal and
uncontrollable in the osseous wound. Thirdly, as the tissue
within the osseous wound was very limited, protein level
measurement could not be achievable to further confirm the
findings in the mRNA level.
Within the limitations of the study, we conclude that the
anti-AGE agents AG and PTB are able to reduce inflamma-
tion via the inhibition of RAGE signaling in the early stage of
osseous wound repair. However, osteogenesis was not
effectively facilitated but potentially retarded under the
current mode of anti-AGE treatment. Further mechanistic
investigations in more clinically relevant models and the
development of vehicles to control the release of anti-AGE
agents precisely are still needed.
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